KOSDAQBiotech & Pharma144510

GC Cell

₩9,730▼ 1.02%2026-11-18 close
Market Cap
₩153.7B
Turnover
₩200M
Volume
20K
Shares out.
15.8M
PER
—
PBR
0.9×
EPS
-₩16,938
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Revenue Declines and Losses, with Overseas Expansion Underway

GC Cell's revenue has fallen for three straight years through 2025 and it has posted operating losses since 2024, while overseas launches and a WHO drug-classification change for its core product, Immuncell-LC, are the next points to monitor.

  1. 1

    Revenue fell from KRW 236.1 billion in 2022 to KRW 165.5 billion in 2025, declining for three straight years from 2023 through 2025.

  2. 2

    The company posted operating losses in both 2024 and 2025; the 2025 operating loss of KRW 13.8 billion was narrower than the KRW 20 billion loss in 2024.

  3. 3

    The 2025 net loss attributable to controlling shareholders was KRW 272.9 billion, and the fourth quarter alone accounted for KRW 243.2 billion of it.

  4. 4

    Third-quarter 2026 revenue rose to KRW 44.4 billion, the second straight quarterly increase, but the operating loss of KRW 2.52 billion widened from a year earlier.

  5. 5

    Immuncell-LC has been administered to its first patient in Indonesia, talks on introduction in Türkiye are ongoing, and its detailed WHO code applies from January 2027.

02

Business structure

GC Cell is a cell and gene therapy developer within the GC Biopharma group. The company says it has experience across the full cycle, from product development through GMP manufacturing to commercialization.

Its core product, Immuncell-LC, isolates immune cells from a patient's blood, cultures them and returns them to the patient, and it is approved in Korea as a liver cancer treatment.

In a retrospective analysis of liver transplant patients presented in February 2026, the two-year recurrence-free survival rate was 87.5% in the treated group versus 62.9% in the control group.

In 2024 the company signed a technology transfer and licensing agreement with Indonesia's Bifarma for local commercialization, and the first Indonesian patient was treated in May 2026.

In October 2026, Türkiye's health ministry requested a visit to the company's headquarters and manufacturing facility, and both sides discussed licensing and commercialization steps; an NK cell therapy is also under review there.

On the technology side, the company registered patents in Korea and Japan in February 2026 for a CIITA control technology aimed at reducing immune rejection in allogeneic cell therapies.

Allogeneic products face a limit because the patient's immune system can attack cells from another person, which is the problem this platform is meant to ease.

Manufacturing capability is a competitive point the company emphasizes, and its claim that Immuncell-LC holds the world's largest manufacturing record among cell therapy products is the company's own statement.

On regulation, the WHO drug classification now places the product in the antineoplastic cell and gene therapy category. The business combines domestic product sales, overseas technology transfer and platform patents.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩45B-₩400M−0.9%
2025Q4₩38B-₩4.3B−11.4%
2026Q1₩37.4B-₩5.1B−13.7%
2026Q2₩41.6B-₩1B−2.4%
2026Q3₩44.4B-₩2.5B−5.7%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩236.1B₩44.3B₩25B18.8%4.6%24.0%
2023₩187.5B₩4.1B-₩200M2.2%0.0%22.8%
2024₩174.5B-₩20B-₩73.9B−11.5%−16.1%25.1%
2025₩165.5B-₩13.8B-₩272.9B−8.3%−146.4%59.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

Annual revenue fell from KRW 236.1 billion in 2022 to KRW 187.5 billion in 2023 (down 20.6% year on year), KRW 174.5 billion in 2024 (down 7.0%) and KRW 165.5 billion in 2025 (down 5.1%). Revenue declined for three straight years from 2023 through 2025, and 2022 was the largest year of the 2022 to 2025 period.

Operating profit dropped from KRW 44.3 billion in 2022 to KRW 4.08 billion in 2023 (down 90.8%), and the company swung to an operating loss of KRW 20 billion in 2024. The 2025 operating loss of KRW 13.8 billion was smaller than the year before, but the company has now posted operating losses for two straight years.

The operating margin moved from 18.8% in 2022 to 2.2% in 2023, -11.5% in 2024 and -8.3% in 2025. Net income attributable to controlling shareholders was KRW 25 billion in 2022, turned to a loss of KRW 174 million in 2023, and widened to a loss of KRW 73.9 billion in 2024 and KRW 272.9 billion in 2025.

Total net loss including non-controlling interests was KRW 273.5 billion in 2025, close to the controlling-shareholder figure.

The fourth-quarter 2025 loss attributable to controlling shareholders was KRW 243.2 billion, while that quarter's operating loss was KRW 4.33 billion, so the gap between operating and bottom-line results was large.

Whether non-operating items or one-off charges drove that gap should be checked in the notes to the annual report.

Quarterly revenue in 2026 bottomed at KRW 37.4 billion in the first quarter (down 1.7% from the prior quarter), then rose to KRW 41.6 billion in the second quarter (up 11.3%) and KRW 44.4 billion in the third (up 6.6%), the second straight quarterly increase; third-quarter revenue was still 1.5% below the year-earlier quarter.

Operating losses widened from KRW 397 million in the third quarter of 2025 to KRW 4.33 billion in the fourth quarter and KRW 5.11 billion in the first quarter of 2026, narrowed to KRW 1.01 billion in the second quarter, and widened again to KRW 2.52 billion in the third quarter.

Net income attributable to controlling shareholders turned positive at KRW 2.37 billion in the second quarter of 2026 before returning to a loss of KRW 10.8 billion in the third quarter. The combined net loss attributable to controlling shareholders over the most recent four quarters was KRW 254.5 billion.

Operating cash flow fell from KRW 66.4 billion in 2022 to KRW 9.19 billion in 2025, though it stayed positive from 2023 onward.

05

Industry analysis

Cell therapies depend on manufacturing records and quality control, which act as barriers to entry, and the company emphasizes Immuncell-LC's manufacturing capability.

On regulation, the WHO drug classification serves as a reference point in overseas approvals and licensing talks, which the company says can support its explanation of the product to foreign partners.

On demand, Türkiye's health ministry requested the visit, which the company presents as a sign of local interest, though revenue would only follow after approvals. Across allogeneic cell therapies, immune rejection is a recognized technical limit, and GC Cell presents its CIITA control technology as a way to reduce it.

Larger listed companies in the biopharma sector, such as Samsung Biologics and Celltrion, run different business models from a company concentrated in cell therapy.

Regulatory events such as approvals, classifications and overseas entry appear more likely to shape the earnings inflection than the broader industry cycle. Which of domestic expansion or overseas licensing produces financial results first is likely to define the company's position within the sector.

06

Outlook

The company has pointed to three threads it describes as established. First, overseas expansion of Immuncell-LC: the first patient in Indonesia was treated in May 2026, and the company is using that base to continue licensing talks with other countries.

Second, introduction in Türkiye: after the October 2026 visit, the company says it will keep reviewing approval and commercialization cooperation, with local investment and manufacturing or clinical collaboration also on the table.

Third, regulatory classification: the detailed WHO code L01XL17 applies from January 2027, and the company says it will pursue overseas expansion and technology licensing around that final application date.

On the clinical side, a study in liver transplant patients was presented at a conference in February 2026, and the company intends to widen its use in adjuvant liver cancer therapy. That study is retrospective, so follow-up trial design and results will determine how strong the evidence becomes.

No disclosed figures yet show when or how much overseas licensing will contribute to reported results. Revenue rose for two straight quarters in 2026, but there is no confirmed sign yet that the operating loss structure has changed.

The next checkpoints are the operating loss and operating margin in the 2026 annual report, and whether the Türkiye talks move to a contract or approval stage.

07

Valuation

PER
—
PBR
0.9×
ROE
-84.6%
EPS
-₩16,938
BPS
₩11,597
Dividend per share
₩0

Valuation can be read on two axes, earnings and book value. Because the company has posted net losses over the most recent four quarters, a multiple based on earnings cannot be calculated. On a book-value basis, the share price trades below book value per share, which means there is no premium over net assets.

That reading should be paired with the pace at which losses are eroding equity: total equity was KRW 190.4 billion at the end of 2025, of which KRW 186.4 billion belonged to controlling shareholders. The debt-to-equity ratio rose from 25.1% in 2024 to 59.5% in 2025, with total liabilities of KRW 113.3 billion.

Dividend-based valuation is difficult to apply because the dividend level is low. Over several years, the operating margin has moved from 18.8% in 2022 to negative territory since 2024, so the price-to-book multiple should be read alongside whether earnings recover. Against past multiple ranges, the key starting point is whether the company moves from losses back to profits.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Overseas Launch Steps Advancing

The first patient in Indonesia was treated in May 2026, and in October 2026 Türkiye's health ministry visited the company's headquarters and manufacturing facility to discuss approval and commercialization cooperation. The company says the visit was held at the Turkish side's request. The talks remain at an early stage, so the timing of any revenue is not set.

Data in Liver Transplant Patients

In a retrospective analysis presented in February 2026, the two-year recurrence-free survival rate in the Immuncell-LC group was 87.5%, above 62.9% in the control group. Overall survival was 100% in the treated group versus 81.5% in controls. Because the comparison is retrospective, the strength of the evidence depends on follow-up studies.

Regulatory Classification and Platform Patents

In the WHO classification, Immuncell-LC moved from an other immunostimulant category to the antineoplastic cell and gene therapy category, with the detailed code applying from January 2027. The company sees the classification as a basis for explaining the product in overseas approvals and licensing talks.

In February 2026, patents for the CIITA control technology, which reduces immune rejection in allogeneic cell therapies, were registered in Korea and Japan.

09

Bear factors

Continued Operating Losses and Falling Revenue

Revenue declined for three straight years from 2023 through 2025, and operating losses continued for two straight years in 2024 and 2025. The third-quarter 2026 operating loss of KRW 2.52 billion widened from KRW 397 million a year earlier. Revenue rose for two straight quarters in 2026, but that did not reverse the size of the operating loss.

Large Fourth-Quarter 2025 Loss and Rising Leverage

The fourth-quarter 2025 net loss attributable to controlling shareholders was KRW 243.2 billion, most of the KRW 272.9 billion annual loss for 2025. The debt-to-equity ratio rose from 25.1% in 2024 to 59.5% in 2025. If losses keep accumulating against equity, the financial capacity burden could grow.

Uncertain Financial Scale of Overseas Results

Türkiye is at the stage of discussing approval and commercialization cooperation, while Indonesia is at the stage of licensing talks with other countries following the first treatment. The liver transplant data are retrospective, which limits the strength of the evidence.

No disclosed figures yet show the financial scale of overseas agreements, so it is hard to judge when they will show up in reported results.

10

Risk factors

Finances and Funding

At the end of 2025, total liabilities were KRW 113.3 billion and total equity was KRW 190.4 billion, with a debt-to-equity ratio of 59.5%. Operating cash flow was positive at KRW 9.19 billion in 2025 but small, so continued operating losses could increase funding pressure. The cash impact of losses and the debt structure should be checked in the next periodic report.

Regulatory and Clinical Evidence

The efficacy data for Immuncell-LC in liver transplant patients come from a retrospective analysis, which limits the clinical strength of the evidence. Overseas approval procedures differ by country and could delay timelines.

The detailed WHO code applies from January 2027, so the actual pace at which it appears in overseas approval documents will become clear only after that.

Business Concentration and Technical Limits

Growth expectations are concentrated in Immuncell-LC and overseas technology licensing, so product or partner developments could weigh heavily on results.

Allogeneic cell therapies face the technical limit that a patient's immune system can attack donor cells, so the commercialization timing of the CIITA platform is uncertain. Patent registration does not translate directly into product revenue.

11

What to watch next

  1. January 2027

    The date the detailed WHO ATC code L01XL17 for Immuncell-LC applies. It is the point to check whether the classification change is used in overseas approval documents and licensing talks.

  2. End of March 2027

    The filing deadline for the 2026 annual report. The 2026 full-year operating loss, the quarterly profit trend and the full-year operating margin are the next points to check.

  3. Mid-May 2027

    The filing point for the first-quarter 2027 quarterly report, within the 45-day statutory limit. It is the check on whether the operating loss narrowed compared with the KRW 2.52 billion loss in the third quarter of 2026.

  4. After November 2026 (timing not announced)

    The point at which the approval and commercialization talks with Türkiye's health ministry move to a contract or approval stage. No timing has been announced.

12

Overall view

GC Cell's 2025 revenue fell to KRW 165.5 billion, down for three straight years, and operating losses continued for two straight years in 2024 and 2025.

The fourth quarter accounted for KRW 243.2 billion of the KRW 272.9 billion net loss attributable to controlling shareholders in 2025, showing a large swing within the year. Revenue rose for two straight quarters in 2026, but the third-quarter operating loss of KRW 2.52 billion was wider than a year earlier.

Bullish factors include the advancing overseas launch steps for Immuncell-LC, retrospective data in liver transplant patients, and the WHO classification and CIITA patent.

Bearish factors include continued losses, a higher debt-to-equity ratio, and the fact that no disclosed figures yet show the financial scale of overseas deals.

Both sets of factors carry equal weight, so the starting point for review is checking the operating loss size and whether overseas agreements reach reported results in the next periodic report. Valuation is best read by pairing the price-to-book multiple with the loss trend.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. viva100.com
  2. news.nate.com
  3. view.asiae.co.kr
  4. news.bizwatch.co.kr
  5. ngonews.kr
  6. m.news.nate.com
  7. view.asiae.co.kr
  8. mt.co.kr
  9. etnews.com
  10. inthenews.co.kr
  11. betanews.net
  12. sateconomy.co.kr
  13. medipana.com
  14. newscj.com
  15. medifonews.com
  16. meconomynews.com
  17. edaily.co.kr
  18. comp.fnguide.com

Report written 2026-11-16 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis